Background and objectives Higher serum total alkaline phosphatase (AP) levels are associated with increased serum C-reactive protein (CRP) levels and mortality in the general and CKD populations. It is unclear to what extent these associations are related to bone disease.
Introduction
High serum total alkaline phosphatase (AP) levels are associated with increased serum C-reactive protein (CRP) levels (1, 2) . Increased serum total AP levels have also been associated with increased mortality in the general, CKD, and dialysis populations (3) (4) (5) (6) (7) (8) , even after adjustment for liver function tests (3) (4) (5) 7, 8) . However, it is unclear whether the increased mortality associated with elevated serum total AP levels is the result of bone disease or other mechanisms.
Skeletal AP is produced exclusively by osteoblasts and plays an important role in bone mineralization by hydrolysis of pyrophosphate (9) . Skeletal and liver AP isoenzymes differ only by post-translational glycosylation (10) . Specific skeletal AP mAbs have been developed for use in radioimmunologic and immunoenzymatic assays (11) (12) (13) (14) . Serum levels of total as well as skeletal AP were measured in the 1999-2004 National Health and Nutrition Examination Survey (NHANES). Therefore, we examined whether the associations of serum total AP with inflammation and mortality are accounted for by serum levels of skeletal AP in the non-CKD and CKD populations using 1999-2004 NHANES data.
Materials and Methods

Study Population and Baseline Data
The National Center for Health Statistics (NCHS) conducts NHANES, a continuous annual survey, to sample a representative population of the noninstitutionalized US population. The study population for the current analysis consists of 10,707 NHANES participants from the 1999-2004 survey datasets who were aged $20 years with an estimated GFR (eGFR) #150 ml/min per 1.73 m 2 and nonmissing data for serum skeletal AP and follow-up mortality.
NHANES data collection details have been published elsewhere (15, 16) . In brief, computer-assisted household interviews are conducted and followed by a physical examination conducted in the Mobile Examination Center. Serum high-sensitivity CRP was measured by latex-enhanced nephelometry using reagents from Dade Behring Diagnostics Inc (Newark, DE). During NHANES 1999 -2000 and 2003 -2004 , serum skeletal AP levels were measured using the Tandem-MP Ostase ImmunoEnzymetric assay (Hybritech Inc, San Diego, CA) (17 
Follow-Up Data
The NCHS created a NHANES Linked Mortality File through December 31, 2006 using a probabilistic match between NHANES III and National Death Index death certificate records (19) .
Statistical Analyses
NHANES is based on a complex probability sample design. We used the svy suite of commands in Stata 11 (Stata, College Station, TX) and followed the analytical guidelines for NHANES data proposed by the NCHS (20) . The svy suite of commands in Stata use the complex survey design of NHANES to calculate the expected means and proportions of the entire US noninstitutionalized civilian population; hence, we reported estimated means and 95% confidence intervals (95% CIs).
Predictor Variables. Serum total and skeletal AP levels were positively skewed and thus log-transformed and then divided by the logarithm of 2 in order to express results as the increase in the odds ratio (OR) or hazard ratio (HR) for every two-fold increase in AP levels.
We estimated nonskeletal AP as residuals of a linear regression of log-transformed total AP on skeletal AP to represent the component of total AP that was statistically uncorrelated with skeletal AP. The regression coefficients of the residuals in multivariable models describe the association of the outcome with nonskeletal AP.
Associations of Serum Total AP and Serum Skeletal AP with Elevated CRP. Elevated CRP was defined as serum CRP .3 mg/L (21, 22) . The joint relationship of elevated serum CRP with serum skeletal AP and the residuals was first examined by fitting a weighted generalized additive logistic regression model that included a two-dimensional nonparametric local regression term for serum skeletal AP and the residuals as well as linear terms for the following covariates: demographics (age, sex, and race), systolic and diastolic BP, waist circumference, eGFR, liver disease, hemoglobin, serum calcium, phosphorus, aspartate transaminase (AST), alanine transaminase (ALT), g-glutamyl transpeptidase (GGT), bilirubin, and albumin. This analysis showed that the association of elevated serum CRP with serum skeletal AP and the residuals was additive, so that each factor could be analyzed separately in multiple regression models without incorporating interaction terms (Supplemental Figure 1) .
Separate multivariable logistic linear regression models were used to relate elevated CRP to either serum total AP concentrations or both serum skeletal AP concentrations and nonskeletal AP, after controlling for covariates designated above. Linearity of the logit of the probability of elevated CRP was assessed for numeric variables by adding quadratic terms.
Associations of Mortality with Serum Total and Skeletal AP. Separate multivariable Cox regression analyses were used to relate mortality to serum total and both serum skeletal and nonskeletal AP with covariate adjustment for the same factors designated above for the logistic regressions of CRP plus serum CRP and white blood cell count.
The assumption of proportional hazards was examined by comparing the logarithm of the HR for each predictor variable in the first 36 months of follow-up with the logarithm of the HR of the predictor variables after 36 months. No deviation from proportional hazards was detected with respect to serum total AP or serum skeletal AP.
The assumption of linearity for the log-transformed hazard function was assessed as described for the logistic regression models of elevated CRP. We tested for an interaction between serum skeletal AP and the residuals by adding the product of these factors to the Cox regression model.
Examination of Effect Modification by CKD. The above logistic and Cox regression analyses were conducted separately in CKD and non-CKD subpopulations. CKD was defined as eGFR ,60 ml/min per 1.73 m 2 . Individual logistic and Cox regression coefficients were compared between the two populations based on the ratio of the differences between the coefficients from the two populations to the square root of the sum of the squares of the corresponding SEMs.
In sensitivity analyses, serum PTH was added as a new measurement in the 2003-2004 dataset (n=2190), but only 10 deaths were reported over an average follow-up of 35.466.9 months in this subpopulation. Therefore, the association of AP with elevated CRP was examined after adjustment for PTH in this subpopulation, but a similar analysis investigating the effect of adjustment for PTH on the association of mortality with AP could not be performed.
Due to a higher rate of missing skeletal AP measurements during 2003-2004 (see below), all analyses not involving serum PTH were repeated using only the 1999-2002 data.
Results
There were 8533 participants aged $20 years with eGFR #150 ml/min per 1.73 m 2 in the NHANES 1999-2002 dataset, 8515 of whom (99.8%) had nonmissing serum total AP, skeletal AP, and mortality. The fraction with missing data was greater in 2003-2004 because NHANES obtained skeletal AP only for individuals aged #49 years in this cohort; during this period, 2192 of 4374 (50.1%) participants aged $20 years with an eGFR #150 ml/min per 1.73 m 2 had nonmissing serum total, skeletal AP, and mortality. In total, the current analyses included 10,707 adults aged $20 years with eGFR ,150 ml/min per 1.73 m 2 in the combined cohort with nonmissing data for serum total AP, skeletal AP, and mortality.
The mean (6 SD) age of participants was 43.6612.4 years, and 48.9% of the study population were men, 71.2% were Caucasian, and 6.7% had CKD. Levels of serum total AP, skeletal AP, and nonskeletal AP (residuals) were skewed ( Figure 1A ). The median (25th and 75th percentiles) serum skeletal AP levels were 12.7 mg/L (10.0, 16.5) and median serum total AP levels were 67.6 IU/L (55.3, 83.0).
The baseline clinical characteristics of low and high serum nonskeletal AP levels (defined by median value of the residuals) are summarized in Table 1 . As expected, serum total AP levels were higher in the high nonskeletal AP group but there were no differences in serum skeletal AP levels between the two groups. Older age, male sex, diabetes, cardiovascular conditions, and greater waist circumferences were associated with higher levels of serum nonskeletal AP levels.
The serum total AP levels exhibited a moderately strong correlation with serum skeletal AP levels, with weighted Pearson r of 0.74 (P,0.001), indicating that approximately 55% of the variation in serum total AP could be accounted for by the variation in serum skeletal AP levels ( Figure 1B) .
Associations of AP with Elevated CRP Levels
The two-dimensional nonparametric local regression for serum skeletal AP and the residuals indicated that the relationship of these factors with elevated CRP was additive across the full range of both predictor variables (Supplemental Figure 1) .
In spite of their moderately strong correlation with each other, serum skeletal and total AP exhibited qualitatively different relationships with CRP (Table 2 ). Serum total AP was directly associated with the risk of an elevated CRP (adjusted OR, 1.96; 95% CI, 1.74-2.22), when adjusted for demographics, BP, waist circumference, liver disease, liver function tests, serum calcium, phosphorus, albumin, hemoglobin, and eGFR. Similar findings were observed when further adjusted for diabetes, myocardial infarction, congestive heart failure, and stroke. In a separate multivariable logistic regression model (Table 2) including both serum skeletal and nonskeletal AP, each doubling of nonskeletal AP was strongly associated with elevated CRP (for each doubling: OR, 4.64; 95% CI, 3.92-5.49), whereas skeletal AP was not (for each doubling: OR, 1.02; 95% CI, 0.93-1.12).
As shown in Figure 2 , after adjusting for the above covariates, serum total AP and nonskeletal AP were associated with increased odds of elevated CRP in both the non-CKD and CKD subpopulations. Higher levels of serum skeletal AP levels were not associated with elevated CRP in either subpopulation. None of these ORs differed significantly between the CKD and non-CKD subpopulations (P.0.30 for each of the three OR comparisons).
Associations of Serum AP Levels with Mortality
There were 715 deaths over a total of 54,089 person-years of follow-up. As shown in Table 3 , serum total AP was directly associated with increased mortality (for each doubling of serum total alkaline phosphatase: HR, 1.28; 95% CI, 1.08-1.52), whereas serum skeletal AP was not (HR, 1.07; 95% CI, 0.93-1.23), when adjusted for baseline clinical characteristics including liver disease and liver function tests. As with elevated CRP, nonskeletal AP had the strongest association with mortality (Table 3) . Further adjustment for CRP and white blood cell count as well as cardiovascular conditions and diabetes (Table 3) did not significantly change these results.
There were 438 deaths over 49,541 person-years in the non-CKD subpopulation and 277 deaths over 4548 personyears in the CKD subpopulation. As shown in Figure 3 , higher levels of serum total AP were associated with increased mortality in the non-CKD subpopulation but not in the CKD subpopulation. The regression coefficients of serum total AP for mortality in the non-CKD and CKD subpopulations were statistically different (P=0.04) from each other. Results for the associations of nonskeletal AP with mortality in the CKD and non-CKD populations were similar to that of serum total AP.
On the other hand, serum skeletal AP was not associated with increased mortality in either the non-CKD or the CKD subpopulations. The regression coefficients of serum skeletal AP with mortality were not different between the non-CKD and CKD subpopulations (P=0.50).
Sensitivity Analyses. In additional sensitivity analysis of the subpopulation with PTH measurements (Supplemental Table 1 ), the associations of the serum total, skeletal, or nonskeletal APs with serum CRP were not substantially altered after adjustment for PTH in addition to the other covariates.
Of the 8533 participants aged $20 years with eGFR #150 ml/min per 1.73 m 2 in the NHANES 1999-2002 dataset, 8515 (99.8%) had nonmissing serum total AP, skeletal AP, and mortality. When analyses were restricted to this cohort, the associations of total, skeletal, and nonskeletal AP with elevated CRP and mortality were similar to the 1999-2004 cohort.
Discussion
Elevated serum total AP levels are commonly seen in nondialysis CKD and dialysis populations and are thought to be the result of increased osteoblastic activity that occurs Figure 2 . | Associations of serum total, skeletal, and nonskeletal alkaline phosphatase (residuals) levels with elevated serum CRP in non-CKD (n=936) and CKD (n=9771) subpopulations in the 1999-2004 National Health and Nutrition Examination Survey (n=10,707). Adjusted for demographics (age, sex, and race), systolic and diastolic BP, waist circumference, estimated GFR, liver disease, serum calcium, serum phosphorus, serum aspartate transaminase, alanine transaminase, g-glutamyl transpeptidase, bilirubin, albumin, and hemoglobin. CRP, C-reactive protein. with secondary hyperparathyroidism. In hemodialysis patients, elevated serum AP levels have been shown to be independently associated with increased mortality in several studies (5) (6) (7) (8) . More recently, elevated serum total AP levels have also been shown to be associated with increased mortality in the CKD population (4) and the general population (3,23) independent of liver disease. The liver and bones are the major sources that contribute to serum AP levels. In the above studies (3, 4, 23) , however, adjustment for liver disease or liver function tests did not eliminate the associations of serum total AP with mortality, implying that bones are the culprit. The results of this study indicate that in healthy, asymptomatic, communitydwelling adults, approximately 55% of the variations in serum total AP levels were accounted for by serum skeletal AP levels. Therefore, it is expected that serum skeletal AP levels will follow the known associations of serum total AP levels with mortality (3) (4) (5) (6) (7) (8) 23) .
Nonetheless, in both non-CKD and CKD subpopulations, in contrast to the associations of serum total AP levels, serum skeletal AP levels were not associated with elevated CRP (Figure 2 and Table 2 ). This finding suggests that the associations of serum total AP level with inflammation are driven by the fraction of serum total AP that is not accounted for by serum skeletal AP levels (i.e., nonskeletal AP). Further analysis of the residuals supports this conclusion (Table 2 and Figure 2) . The above analyses were performed with adjustments for liver function tests. Hence, mechanisms other than liver and bone disease are likely implicated for this association. AP is also produced by circulating leukocytes. We speculate that increased serum levels of total AP might reflect increased activation of neutrophils because these cells have been shown to increase the expression of AP in response to LPS (24) . Further studies are warranted to determine whether indeed higher serum levels of total AP in the asymptomatic, community-dwelling population reflects intermittent or chronic neutrophil activation.
Serum skeletal AP levels were not associated with increased mortality in both non-CKD and subpopulations ( Figure 3 ). It should be noted that most individuals in the CKD subpopulation in this cohort had only modest decreases in GFR. It is possible that the associations of serum skeletal AP levels with elevated serum CRP levels and mortality might be different in more advanced CKD.
In subgroup analyses, serum total AP and nonskeletal AP were associated with increased mortality in the non-CKD population only. In CKD subpopulation, higher serum total AP and nonskeletal AP levels were not associated with increased mortality. Our previous analyses using the African-American Study of Kidney Disease and Hypertension study data in more advanced CKD patients (4) and the HEMO study data in dialysis patients (8) suggested that higher serum total AP levels were associated with increased mortality. This apparent discrepancy may be due to the lower number of deaths, hence lower statistical power in this study. Nonetheless, in both CKD and non-CKD subpopulations, higher serum total AP and nonskeletal AP were associated with elevated CRP.
It is possible that the skeletal AP assay might also have cross-reacted with nonskeletal AP. If that is the case, then one would expect that the associations of serum skeletal AP with inflammation and mortality would track that of serum total AP. However, those associations have been discordant in this study.
The strengths of this study include very careful data collection in NHANES. The major limitations of this study include those of all observational studies that use existing data. The observational nature of the study prohibited inference beyond associations and unmeasured residual confounding needs to be considered while interpreting the results. There were no longitudinal data available on serum total and skeletal AP levels in this dataset. Two different assay methodologies for bone AP were used between data collection years. To minimize the potential inconsistencies in assay results, NHANES performed a cross-over study to establish regression equations to convert results between the two assay methods. Limited mortality data are available in the subpopulation (2003-2004 dataset) in which serum PTH levels were measured; however, the associations of AP with elevated serum CRP were similar with or without adjusting for PTH levels.
In summary, elevated serum skeletal AP levels were not associated with elevated serum CRP levels and mortality. Hence, bone disease is unlikely to be the explanation for the reported associations of total AP with inflammation and mortality that have been reported in several other studies. Further studies are warranted to determine the mechanisms by which increased mortality risk is associated with higher levels of serum total AP as well as whether high levels of serum skeletal AP is associated with inflammation and mortality in advanced CKD. . Adjusted for demographics (age, sex, and race), systolic and diastolic BP, waist circumference, estimated GFR, liver disease, serum calcium, serum phosphorus, serum aspartate transaminase, alanine transaminase, g-glutamyl transpeptidase, bilirubin, albumin, and hemoglobin.
